Latest Articles

All News Scientific

Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer - The Lancet

Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer The Lancet

Published: April 30, 2024, 7 a.m.

Read Full Article

New blood test shows promise in early detection of ovarian cancer - News-Medical.Net

New blood test shows promise in early detection of ovarian cancer News-Medical.Net

Published: April 28, 2024, 7 a.m.

Read Full Article

Research progress in endometriosis-associated ovarian cancer - Frontiers

Research progress in endometriosis-associated ovarian cancer Frontiers

Published: April 24, 2024, 7 a.m.

Read Full Article

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer - OncLive

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer OncLive

Published: April 24, 2024, 7 a.m.

Read Full Article

GSK's endometrial cancer drug receives FDA approval - ShareCast

GSK's endometrial cancer drug receives FDA approval ShareCast

Published: April 24, 2024, 7 a.m.

Read Full Article

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire

Published: April 24, 2024, 7 a.m.

Read Full Article

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Investor Relations | Karyopharm Therapeutics

Published: April 24, 2024, 7 a.m.

Read Full Article

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses Nature.com

Published: April 23, 2024, 7 a.m.

Read Full Article

$400,000 awarded to ovarian cancer researchers - fredhutch.org

$400,000 awarded to ovarian cancer researchers fredhutch.org

Published: April 22, 2024, 7 a.m.

Read Full Article

Found in Plastic, Cosmetics, and More: New Study Links Everyday Chemicals to Increased Risk of Cancer - SciTechDaily

Found in Plastic, Cosmetics, and More: New Study Links Everyday Chemicals to Increased Risk of Cancer SciTechDaily

Published: April 20, 2024, 7 a.m.

Read Full Article

Link copied to clipboard!